SCHEMBL1870494

SCHEMBL1870494

CC1=NCCc2sccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 3/20 0.60
MAOA P21397 4/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
PLK4 O00444 1/20 0.37
CHEK1 O14757 1/20 0.37
AURKA O14965 1/20 0.37
DAPK3 O43293 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
PAK4 O96013 1/20 0.37
PIM1 P11309 1/20 0.37
PDGFRA P16234 1/20 0.37
PRKACA P17612 1/20 0.37
LTK P29376 1/20 0.37
GRK5 P34947 1/20 0.37
KDR P35968 1/20 0.37
MAP2K2 P36507 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8060969 0.75 NOS2 (1.00) NOS2ALDH1A1PLK4CHEK1AURKA
SCHEMBL8104298 0.75 NOS2 (0.55) NOS2PLK4CHEK1AURKADAPK3
SCHEMBL12158615 0.74 NOS2 (0.50) NOS2ALDH1A1PLK4CHEK1AURKA
Iodide SCHEMBL8099764 0.73 NOS2 (0.96) NOS2PLK4CHEK1AURKADAPK3
SCHEMBL9216129 0.72 NOS2 (0.51) NOS2PLK4CHEK1AURKADAPK3
SCHEMBL17807492 0.69 NOS2 (0.53) NOS2ALDH1A1PLK4CHEK1AURKA
SCHEMBL3307465 0.69 NOS2 (0.61) NOS2MAOAKDM4EMAPTALDH1A1
SCHEMBL15267114 0.69 NOS2 (0.47) NOS2KDM4EALDH1A1PLK4CHEK1
SCHEMBL14498864 0.67 NOS2 (0.41) NOS2MAPTPLK4CHEK1AURKA
SCHEMBL3872610 0.67 NOS2 (0.50) NOS2PLK4CHEK1AURKADAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059209-A1 THERAPEUTIC AGENTS AND USES THEREOF ANKH LIFE SCIENCES LIMITED (IE) 2025-02-20 US disclosed
US-12129265-B2 Therapeutic agents and uses thereof ANKH LIFE SCIENCES LIMITED (IE) 2024-10-29 US disclosed
EP-4185288-A1 THERAPEUTIC AGENTS AND USES THEREOF Ankh Life Sciences Limited (IE) 2023-05-31 EP disclosed
CN-115916195-A Therapeutic agents and uses thereof 安科生命科学有限公司 2023-04-04 CN disclosed
US-20220033417-A1 THERAPEUTIC AGENTS AND USES THEREOF ANKH LIFE SCIENCES LIMITED (IE) 2022-02-03 US disclosed
US-20220033417-A1 THERAPEUTIC AGENTS AND USES THEREOF ANKH LIFE SCIENCES LIMITED (IE) 2022-02-03 US disclosed
WO-2022019892-A1 THERAPEUTIC AGENTS AND USES THEREOF ANKH LIFE SCIENCES LIMITED (IE) 2022-01-27 WO disclosed
US-7947689-B2 Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators MERZ PHARMA GMBH & CO. KGAA (DE) 2011-05-24 US disclosed
US-7947689-B2 Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators MERZ PHARMA GMBH & CO. KGAA (DE) 2011-05-24 US disclosed
US-7947689-B2 Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators MERZ PHARMA GMBH & CO. KGAA (DE) 2011-05-24 US disclosed
US-20080039476-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine MERZ PHARMA GMBH & CO. KGAA (DE) 2008-02-14 US disclosed
WO-2008015270-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE MERZ PHARMA GMBH & CO. KGAA (DE) 2008-02-07 WO disclosed
WO-2008015270-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE MERZ PHARMA GMBH & CO. KGAA (DE) 2008-02-07 WO disclosed
US-5036066-A Muscle relaxants, anxiolytic agents, anticonvulsants HOFFMANN-LA ROCHE INC. (US) 1991-07-30 US disclosed
EP-0183994-B1 TRICYCLIC PYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1990-03-21 EP disclosed
US-4889848-A 4-OXO-4H-BENZO(A)QUINOLIZINES; MUSCLE RELAXANTS; SEDATIVES; ANTICONVULSANTS; ANXIOLYTIC AGENTS HOFFMANN-LA ROCHE INC. (US) 1989-12-26 US disclosed
US-4839365-A Thienopyridine derivatives useful in treating gastric ulcers SHINOGI & CO., LTD. (JP) 1989-06-13 US disclosed
EP-0292051-A2 Thienopyridine derivatives SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1988-11-23 EP disclosed
US-4735940-A Tricyclic pyridine derivatives and pharmaceutical compositions HOFFMANN-LA ROCHE INC. (US) 1988-04-05 US disclosed
EP-0183994-A1 Tricyclic pyridone derivatives F. HOFFMANN-LA ROCHE AG (CH) 1986-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059209-A1 THERAPEUTIC AGENTS AND USES THEREOF MCL1, RNASE1, HNMT NOS2 3574/4885MAOA 115/4885KDM4E 978/4885
US-12129265-B2 Therapeutic agents and uses thereof MCL1, BCL9, RNASE1 NOS2 3668/4885MAOA 74/4885KDM4E 1224/4885
US-20080039476-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine GRM5, GRM3, GRM1 NOS2 2895/4885MAOA 2093/4885KDM4E 1834/4885
US-20220033417-A1 THERAPEUTIC AGENTS AND USES THEREOF MCL1, BCL9, RNASE1 NOS2 3668/4885MAOA 74/4885KDM4E 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.